Immune to Cancer: The CRI Blog
-
ASCO17: Day 2 Immunotherapy Highlights
Day 2 at the 2017 annual meeting of the American Society of Clinical Oncology further highlighted immunotherapy's…
-
ASCO17: Day 1 Immunotherapy Highlights
Day 1 at the 2017 annual meeting of the American Society of Clinical Oncology demonstrated immunotherapy’s potential…
-
June is Cancer Immunotherapy Month
We love the month of June! The beautiful summer sunshine, the soft breezes…and of course, all the…
-
ASCO17: Exploring the Past, Present, and Future of Immunotherapy
Immunotherapy is poised to shine at ASCO17
-
Immunotherapy Makes History with Latest Cancer Approval
The FDA’s biomarker-based approval of Keytruda was the first of its kind
-
FDA approves Keytruda combo for first-line lung cancer treatment
Patients in the U.S. who have advanced nonsquamous non-small cell lung cancer can now receive Keytruda as…
-
Durvalumab Becomes Newest Immunotherapy Approved for Advanced Bladder Cancer
Durvalumab marks AstraZeneca’s first immunotherapy approval
-
Meet Ariella: Captain of Team Natural Killer Cells in the Answer to Cancer 5K Survivors Walk
Ariella was diagnosed with Hodgkin lymphoma in 2010, but treatment with the immunotherapy drug nivolumab changed everything and…
-
NY-ESO-1 Identified as a Promising Vaccine Target in Ovarian Cancer Patients
New study reveals effectiveness of immunotherapy vaccine against aggressive ovarian tumors.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.